Nektar Therapeutics

US$37.26As of Sun 8 Nov 2026, 12:00 UTC
NASDAQ:NKTRHealthcare
Country USA
PE (Fwd) •••
TSR 10Y CAGR (14.82%)
Div yield —
ROE (35.75%)
Biotechnology
Beta (5Y) 1.42
PE TTM —
TSR TTM (42.62%)
Mkt cap US$1.272B
ROIC (51.66%)
SE Grade™
Value
Quality
Moat
Consensus
Reference
$47
26.06%
(78.72%)
Hold 6|7|6|3|8
4Q25
1Q26
2Q26
3Q26
Earnings per share$
0.50
0.48
0.46
0.45
33.68%
16.02%
14.24%
0.25%
Revenue$M
155.1
160.9
167.6
166.3
3.02%
9.09%
8.01%
7.45%
Peers (US$1.272B)
Cap (US$)
PE
1.292B
—
1.273B
16.58x
Capital
TTM
5Y
10Y
Leveragex
1.792
(0.129)
(0.114)
EBIT/Intx
0.399
0.041
0.044
Own earn%
(2.76)
(165.31)
(130.25)
Sh yield%
38.51
15.29
19.87
Owners
Insiders/Inst%
11.10
43.07
Short interest%
5.67
SBC / revenue%
3.21
Record
10Y
Profitable years
10/10
Revenue growth years
10/10
EPS growth years
10/10
Dividend streakyrs
2
Op margin range%
2–6
$1 testx
—
Incr. ROIC%
25